VIRAL LOAD
Delphic utilises Roche Diagnostic's FDA and CE-IVD-approved COBAS technology to produce fully-automated real-time PCR viral load results in its ISO 9001:2000 certified laboratory.
We can also process your CD4/CD8 samples and provide the results on a combined VL/CD4 report (click here for details).
Turnaround time - 5 working days
|
 |
| Fully automated Real-Time PCR |
| Roche COBAS AmpliPrep (FDA/CE-IVD approved) |
| Roche COBAS TaqMan (CE-IVD approved) |
| Roche HIV-1 viral load assay (CE-IVD approved) |
|
|
VIRAL RESISTANCE TESTING
Delphic supplies Virco's viral resistance testing genotype that uses the world’s largest HIV drug resistance database of matched genotypes and phenotypes to provide an accurate and comprehensive phenotypic resistance profile. Delphic also supplies Virco’s phenotype that provides a quantitative and direct measure of HIV drug susceptibility.
GENOTYPE
Virco®TYPE HIV-1 is an HIV-1 genotype-analysis system that combines Genotype, Phenotype and Additional Clinical Information, all in one easy-to-use report.
Virco®TYPE HIV-1 is the first HIV-1 resistance test report that applies two consistenty derived Clinical Cut-Off values for better treatment selection.
PHENOTYPE
The Antivirogram® is a conventional phenotypic resistance assay that measures, in controlled laboratory conditions, the level of resistance of the HIV population derived from an individual patient to each of the currently approved NRTI, NNRTI and PI. This resistant ‘behaviour’ of the virus usually represents the combined net effects of many different mutations and the complex interactions between them, including genetic changes that have not even been identified yet. Contrary to genotyping, phenotypic resistance testing provides a direct measure of resistance.
For further details on these products please visit: www.vircolab.com
TROPISM
The SensiTrop™ II HIV Co-Receptor Tropism Assay from Pathway Diagnostics is now available from Delphic at a competitive cost and to a 2 week turnaround time. This new, highly sensitive, molecular diagnostic test supports the use of Pfizer’s EMEA approved CCR5 antagonist Celsentri™ (maraviroc), detecting down to 1% CXCR4 HIV variants in mixtures of CXCR4 and CCR5 HIV.
This is an independent testing service carried out in Pathway Diagnostics’ laboratory based in Malibu, California (CLIA and CAP certification). For further details on Pathway Diagnostics, visit their web-site.
|
|
Sensitivity: SensiTrop™ II has been validated to detect CXCR4-tropic HIV
strains at a level of approximately 1% of the total patient HIV
population.¹
Performance: In a recent blinded study of 100 HIV patient samples, SensiTrop™ II was compared to the Trofile assay and was found to match 97.5% of the CXCR4 results with an overall concordance, based on reportable results, of 87%. The overall concordance of SensiTrop II is similar to published reports of 85% concordance between the Trofile assay and other cell-based assays. ²
¹ Weiser et al. AIDS (2008) 45. p.469-479
² Skrabal et al. J. Clin. Micro. (2007), 45(2). p.279-284
Further information on SensiTrop™ II
Assay specifications |
|
